EGFR and brain neoplasm: Later, dual-imaging modes of the fluorescent dye Alexa 680 and the MRI reagent Gd-DOTA were added to a PMLA scaffold, and the complex was further conjugated with therapeutic monoclonal antibodies (trastuzumab for HER2 targeting and/or cetuximab for EGFR targeting) in order to easily differentiate a simultaneous diagnosis of HER2+ and EGFR+ brain tumors (Fig. 5) [106].